Core Insights - Esperion has appointed Robert E. Hoffman as an independent director and Chairperson of the Audit Committee, effective immediately and May 29, 2025, respectively [1][2] - Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors on June 1, 2025 [1] Company Developments - Robert E. Hoffman brings extensive experience in the biopharmaceutical sector, having held leadership roles in various companies, which is expected to benefit Esperion's commercialization efforts and pipeline expansion [2][4] - The company is focused on developing next-generation ATP citrate lyase inhibitors (ACLYi) to address unmet cardiometabolic needs [5][6] Leadership Background - Mr. Hoffman has previously served as President, CEO, and CFO of Kintara Therapeutics, and held senior financial roles at Heron Therapeutics and Arena Pharmaceuticals, contributing to his expertise in commercialization [2][4] - He is also involved with several other life sciences companies and has served on various financial committees, enhancing his leadership credentials [3][4] Company Overview - Esperion is a commercial-stage biopharmaceutical company that has developed the only FDA-approved oral, once-daily, non-statin medications for patients at risk for cardiovascular disease [5] - The company aims to evolve into a leading global biopharmaceutical entity through commercial execution and international partnerships [6]

to FORM S-1 As filed with the Securities and Exchange Commission on October 27, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...

As filed with the Securities and Exchange Commission on October 24, 2023 Registration No. 333-274864 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 KINTARA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Nevada 2834 99-0360497 (I.R.S. Employer Identificatio ...